Cambridge id 5468550

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯酚醚
• 英文名称: Cambridge id 5468550
• 英文别名: 4-[2-(4-ethylphenoxy)ethyl]morpholine
• 化学式: C₁₄H₂₁NO₂
• mdl: MFCD01308430
• 分子量: 235.32
• InChiKey: DHJNLSFLNAWZIK-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.4
• 重原子数：
  17
• 可旋转键数：
  5
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.571
• 拓扑面积：
  21.7
• 氢给体数：
  0
• 氢受体数：
  3

文献信息

• [EN] PRMT5 INHIBITORS CONTAINING A DIHYDRO- OR TETRAHYDROISOQUINOLINE AND USES THEREOF<br/>[FR] INHIBITEURS DE LA PRMT5 CONTENANT UNE DIHYDRO- OU TÉTRAHYDRO-ISOQUINOLÉINE ET LEURS UTILISATIONS
  申请人：EPIZYME INC

  公开号：WO2014100730A1

  公开（公告）日：2014-06-26

  Described herein are compounds of Formula (A), pharmaceutically acceptable salts thereof, and pharmaceutical compositions thereof. Compounds of the present invention are useful for inhibiting PRMT5 activity. Methods of using the compounds for treating PRMT5- mediated disorders are also described.

  本文描述了式（A）的化合物，其药学上可接受的盐以及药物组合物。本发明的化合物对抑制PRMT5活性是有用的。还描述了利用这些化合物治疗PRMT5介导的疾病的方法。
• Pyrazolopyrimidine derivatives or pharmaceutically acceptable salts thereof
  申请人：Unoki Gen

  公开号：US20070173519A1

  公开（公告）日：2007-07-26

  A pyrazolopyrimidine derivative represented by formula (1) and pharmaceutically acceptable salt thereof exhibit excellent inhibitory activity against MAPKAP-K2. Accordingly, medicines containing this compound as an active ingredient are expected to be effective for treating diseases mediated by MAPKAP-K2 such as, for example, inflammatory disorder, autoimmune diseases, destructive osteopathy, cancer and/or tumor growth.

  由式（1）表示的吡唑吡嘧啶衍生物及其药用盐对MAPKAP-K2表现出优异的抑制活性。因此，含有该化合物作为活性成分的药物预计对治疗由MAPKAP-K2介导的疾病，如炎症性疾病、自身免疫疾病、破坏性骨病、癌症和/或肿瘤生长等方面具有有效性。
• [EN] SOMATOSTATIN RECEPTOR ANTAGONIST COMPOUNDS AND METHODS OF USING THE SAME<br/>[FR] COMPOSÉS ANTAGONISTES DU RÉCEPTEUR DE LA SOMATOSTATINE ET PROCÉDÉS D'UTILISATION ASSOCIÉS
  申请人：CDRD VENTURES INC

  公开号：WO2017136943A1

  公开（公告）日：2017-08-17

  The present invention is directed to somatostatin receptor antagonist compounds having the structure of Formula I, compositions comprising the same, and methods of using such compounds and compositions. The compounds may be useful in the prevention or treatment of hypoglycemia.

  本发明涉及具有式I结构的生长抑素受体拮抗剂化合物，包含该化合物的组合物，以及使用该化合物和组合物的方法。这些化合物可能有助于预防或治疗低血糖。
• LIBRARIES OF DIVERSE MACROCYCLIC COMPOUNDS AND METHODS OF MAKING AND USING THE SAME
  申请人：CYCLENIUM PHARMA INC.

  公开号：US20190153620A1

  公开（公告）日：2019-05-23

  The present disclosure relates to novel macrocyclic compounds and libraries thereof that are useful as research tools for drug discovery efforts. This disclosure also relates to methods of preparing these compounds and libraries and methods of using these libraries, such as in high throughput screening. In particular, these libraries are useful for evaluation of bioactivity at existing and newly identified pharmacologically relevant targets, including G protein-coupled receptors, nuclear receptors, enzymes, ion channels, transporters, transcription factors, protein-protein interactions and nucleic acid-protein interactions. As such, these libraries can be applied to the search for new pharmaceutical agents for the treatment and prevention of a range of medical conditions.

  本公开涉及新颖的大环化合物及其库，这些化合物可作为药物发现工作的研究工具。本公开还涉及制备这些化合物和库的方法，以及使用这些库的方法，例如在高通量筛选中的应用。特别是，这些库可用于评估现有和新鉴定的药理相关靶点的生物活性，包括G蛋白偶联受体、核受体、酶、离子通道、转运蛋白、转录因子、蛋白质相互作用和核酸-蛋白质相互作用。因此，这些库可应用于寻找用于治疗和预防各种医疗状况的新药物。
• SUBSTITUTED 1-AMINOPHTHALAZINE DERIVATIVES, PREPARATION THEREOF AND THERAPEUTIC APPLICATION THEREOF
  申请人：AUGEREAU Jean Michel

  公开号：US20090124624A1

  公开（公告）日：2009-05-14

  The invention concerns 1-amino-phthalazine derivatives of general formula (I): Wherein A, B, L, R, R 1 , R 2 , R 3 , R 4 , R 5 and R 7 are as defined herein. The invention also concerns the preparation of said compounds and their therapeutic use.

  这项发明涉及一般式(I)的1-氨基邻苯二酮衍生物：其中A、B、L、R、R1、R2、R3、R4、R5和R7如本文所定义。该发明还涉及所述化合物的制备及其治疗用途。